Study of two drugs for young children with aggressive brain tumors
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is under 6 years old at diagnosis
- Has a high-risk embryonal brain tumor (like ATRT, certain medulloblastomas, or pineoblastoma)
- Has had brain and spine MRI scans before and after surgery
- Child is generally well enough (Lansky score of 50 or higher, expected to live at least 8 weeks)
- Kidneys, heart, lungs, bone marrow, and liver function are within safe limits
- No prior chemotherapy or radiation (except steroids) and no other active cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial is for children with a rare brain tumor (ETMR) who have not had radiation. Depending on how much tumor is left after surgery and if it has spread, the study compares giving radiation early versus high-dose chemotherapy.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Atypical Teratoid/Rhabdoid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.